2025 年 11 月 28 日 Morgan Stanley & Co., International plc 是最終由摩根士丹利擁有的公司。 交易披露 | 交易方 | 日期 | | 有關證券的說明 | 產品說明 | 交易性質 | 與衍生工具有關 | | | 到期日或清結日 | 參考價 | | 已支付／已收 | 交易後數額（包括 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 的參照證券數目 | | | | | | 取的總金額 | 與其訂有協議或 | | | | | | | | | | | | | | | | 達成諒解的任何 | | | | | | | | | | | | | | | | 人士的證券） | | | Morgan Stanley | 2025年11月 | | 衍生工具 | 其他類別產品 | 客戶主動利便客戶 | ─ | 2,000 | 2030 年 | 6 月 20 | | $7.7800 | $15,560.0000 | ...

可能強制全面要約 就耀才證券金融集團有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說 | 交易性質 | 買入／賣出 | 涉及的股份總 | | 已支付／已收 | 已支付或已收 | 已支付或已收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | | 數 | | 取的總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | | （H） | （L） | | Morgan Stanley | 2025 | 年 | 11 月 | 普通股 | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 買入 | | 8,000 | $62,080.0000 | $7.7600 | $7.7600 | | & Co., | 27 日 | | | | 產生的 Delta 1 產品的對沖活動 | | | | | | | | International plc | | | | 普 ...

完 2025 年 11 月 28 日 可能強制全面要約 就耀才證券金融集團有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | 有關證券的說明 | 產品說明 | 交易性質 | | 與衍生工具有關 | 到期日或清結日 | | 已支付／已收取 | 交易後數額（包括 | | 參考價 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 的參照證券數目 | | | 的總金額 | 與其訂有協議或 | | | | | | | | | | | | | | | | | 達成諒解的任何 | | | | | | | | | | | | | | | | | 人士的證券） | | | | | | | Morgan Stanley | 2025 | 衍生工具 | 其他類別產品 | 客戶主動利便客戶 | ─ | 2,000 | 2030 年 6 月 | $7.7800 | $ ...

Group 1 - The core point of the news is that Yao Cai Securities has extended the deadline for the acquisition offer from Ant Group's subsidiary to March 25, 2026, and the deposit has been increased from HKD 140 million to HKD 164 million, which is 5.83% of the total transaction value [2] - The acquisition offer was initially made on April 25, with Ant Group proposing to acquire approximately 50.55% of Yao Cai Securities at a price of HKD 3.28 per share, totaling HKD 28.14 billion [2] - Following the announcement of the acquisition approval by the Hong Kong Securities and Futures Commission on October 10, Yao Cai Securities' stock price surged by 34.52% [2] Group 2 - The acquisition faced delays due to pending regulatory approvals, as indicated in a statement from Yao Cai Securities on November 11 [3] - Financial data for Yao Cai Securities shows total revenue for fiscal years 2022 to 2024 at HKD 10.14 billion, HKD 10.50 billion, and HKD 11.21 billion, with year-on-year changes of -19.96%, -4.05%, and 3.09% respectively [3] - The net profit attributable to shareholders for the same period is projected at HKD 4.55 billion, HKD 5.43 billion, and HKD 5.06 billion, with year-on-year changes of -20.23%, 10.53%, and -9.95% respectively [3]

Morgan Stanley & Co., International plc 是與要約人有關連的第(5)類別聯繫人。 交易是為本身帳戶進行的。 可能強制全面要約 就耀才證券金融集團有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | 有關證券的說明 | 產品說明 | 交易性質 | 與衍生工具有關 | | | 到期日或清結日 | 參考價 | | 已支付／已收 | 交易後數額（包括 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 的參照證券數目 | | | | | | 取的總金額 | 與其訂有協議或 | | | | | | | | | | | | | | | | 達成諒解的任何 | | | | | | | | | | | | | | | | 人士的證券） | | | Morgan Stanley | 2025年11月 | | 衍生工具 | 其他類別產品 | 客 ...

2025 年 11 月 27 日 可能強制全面要約 就耀才證券金融集團有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | 有關證券的說明 | 產品說明 | 交易性質 | 與衍生工具有關 | | 到期日或清結日 | 參考價 | 已支付／已收取的 | 交易後數額（包括 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 的參照證券數目 | | | | 總金額 | 與其訂有協議或 | | | | | | | | | | | | | 達成諒解的任何 | | | | | | | | | | | | | 人士的證券） | | | Morgan Stanley | 2025年11月 | 衍生工具 | 其他類別產品 | 客戶主動利便客戶 | ─ | 54,000 | 2030 年 6 月 20 | $8.0887 | $436,792.0000 | | 0 | | Capital Services | 26 日 | | ...

| 交易方 | 日期 | | | 有關證券的說 | 交易性質 | 買入／賣出 | 涉及的股份 | 已支付／已收取 | 已支付或已收 | | 已支付或已收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | | 總數 | 的總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | | （H） | （L） | | | Morgan Stanley | 2025 | 11 年 | 月 | 普通股 | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 買入 | 70,000 | $562,012.0000 | $8.2300 | $7.8600 | | | & Co., | 26 日 | | | | 產生的 Delta 1 產品的對沖活動 | | | | | | | | International plc | | | | 普通股 | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 賣出 | 54,000 | $436,792.0000 | $8.2300 | ...

Group 1: Influenza Situation - The influenza activity in China has reached an epidemic level, with most provinces reporting a rapid increase in cases [1] - The latest report indicates that flu-like cases in sentinel hospitals have reached the highest proportion in nearly four years, with northern provinces showing higher rates than southern ones [1] - A total of 955 flu-like outbreaks were reported nationwide, with 741 caused by the H3N2 strain [1] Group 2: Stock Market Overview - The U.S. stock market experienced gains, with the Dow Jones Industrial Average rising by 314.67 points, or 0.67%, to close at 47,427.12 points [2] - The S&P 500 and Nasdaq also saw increases of 46.73 points (0.69%) and 189.1 points (0.82%), respectively [2] - Retail stocks strengthened ahead of the Black Friday shopping season, with Walmart reaching a historic high [2] Group 3: Hong Kong Real Estate Market - The private residential property price index in Hong Kong rose by 0.4% in October, marking five consecutive months of increases [3] - The latest index does not yet reflect the positive impacts of recent interest rate cuts and significant agreements reached during the U.S.-China summit [3] Group 4: Financial Innovations - The Industrial and Commercial Bank of China has successfully conducted offshore foreign currency tri-party repurchase transactions, becoming the first domestic bank to participate in this international market [4] - This innovation enhances the bank's pricing power and operational efficiency while reducing risks and costs associated with traditional bilateral repurchase agreements [4] Group 5: AI Product Launch - Meituan has launched its first AI IDE product, CatPaw, which focuses on agent-driven programming and includes features like code completion and project debugging [5] Group 6: Pharmaceutical Approvals - Boan Biotech's Abicipar injection has received approval for marketing in China, targeting age-related macular degeneration and diabetic macular edema [6] - Eucan Vision Biotech's OT-702, a biosimilar to EYLEA, has also been approved for the same indications in China [7] Group 7: Financial Performance - Haidilao's overseas business reported a revenue of $214 million for Q3, reflecting a year-on-year growth of 7.8% [8] - Yao Cai Securities reported a net profit of HKD 327 million for the six months ending September 30, marking a 4.77% increase year-on-year [9] - NIO's Q3 revenue reached RMB 21.79 billion, with a strong delivery growth of 40.8% year-on-year, and a Q4 revenue guidance of RMB 32.758 billion to RMB 34.039 billion [10] Group 8: Debt Restructuring - Ocean Group's debt restructuring plan for seven domestic bonds, totaling approximately RMB 13.05 billion, has been approved by bondholders [11] Group 9: New Stock Performance - The new Hong Kong stock Quantitative Party saw a nearly 200% increase in its dark market trading, reflecting strong investor interest [12] Group 10: Company Earnings - Alibaba Health reported a net profit of RMB 1.266 billion for the six months ending September 30, a 64.7% increase year-on-year, with total revenue of RMB 16.697 billion [13]

11月25日晚，港股上市公司耀才证券金融发布公告，宣布与蚂蚁集团旗下要约方签订修订协议，将原本 当日到期的收购要约截止日期延长4个月至2026年3月25日。 10月10日晚间，上述收购案进一步推进。耀才证券发布公告称，蚂蚁集团收购耀才证券的事项已经获香 港证监会批准。目前，还需国家发展改革委审批后落定。彼时，港股耀才证券金融（HK.01428）曾因 此消息实现了一波34.52%的大幅上涨。 没想到，11月11日晚，上述收购案出现波折。耀才证券发布消息称，收购要约人蚂蚁集团方面正考虑可 能延长交易的最后截止日期。据悉，此次延期的核心原因在于关键监管审批尚未完成。 从财务数据角度来看，2022财年至2024财年，耀才证券营业总收入分别为10.14亿港元、10.50亿港元及 11.21亿港元，分别实现同比变动-19.96%、-4.05%及3.09%；同期归母净利润分别为4.55亿港元、5.43亿 港元及5.06亿港元，同比变动分别为-20.23%、10.53%及-9.95%。 采写：南都·湾财社记者 吴鸿森 收购案起"波折"，蚂蚁集团或延期收购耀才证券 蚂蚁集团收购获香港证监会批准，耀才证券大涨近35% 同时，蚂蚁 ...

本文源自：金融界AI电报 耀才证券金融(01428.HK)发布截至2025年9月30日止六个月的中期业绩，收入4.97亿港元，同比增长 10.72%;净利润3.27亿港元，同比增长4.77%;基本每股盈利19.26港仙。 ...